IUD and Norethindrone Acetate for Treatment of Endometriosis
Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
Endometriosis is the most common reproductive disease afflicting young women, often leading
to debilitating chronic pelvic pain and impaired quality of life. Safe, effective, and
convenient long-term treatments are lacking for adolescents and young adults. The
levonorgestrel-containing IUD (LNG-IUD) represents an attractive long-term drug delivery
system for the treatment of endometriosis during adolescence and young adulthood. However,
while the LNG-IUD has an acceptable safety profile, it is not associated with a favorable
bleeding profile and may not fully suppress endometriosis pain when used as monotherapy.
Investigators hypothesize that the addition of NETA will improve bleeding patterns, maximize
pain control, and improve continuation rates of the IUD when the two medications are used in
combination. This proposed prospective trial provides the ideal context in which to
investigate these clinical questions and advance research on the best treatments for
endometriosis.